Analysis of Adverse Events in the Treatment of Patients with Non-Valvular Atrial Fibrillation with Oral Anticoagulants: Data from the "ANTEY" Observational Study.
Sergey Yu MartsevichYulia V LukinaNatalia P KutishenkoAnton R KiselevOksana M DrapkinaPublished in: Pharmaceuticals (Basel, Switzerland) (2022)
The most typical and common AEs in real-world clinical practice settings treatment with OACs were bleedings, the incidence of which was approximately 8% to 9% in the treatment with NOACs and was much higher with warfarin, bleedings in the treatment with OACs are statistically significantly associated with nonadherence to the use of these drugs in the future.